



Trend of OPDIVO

Sales Trend of OPDIVO by Each Cancer



The result of Clinical Trial - NSCLC 1L (PD-L1 negative) -

CheckMate 9LA Trial



OPDIVO + YERVOY + Chemo

Five-year overall survival rates


22%

Six-year overall survival rates

20%

Carbone DP, et al. ESMO Open. 2025 Jun;10(6):105123

CheckMate 227 Trial



OPDIVO + YERVOY

Five-year overall survival rates


19%

Six-year overall survival rates

16%

Suresh S. Ramalingam, et al. WCLC2023#OA14.03

Prescription Ratio in Patients Newly Treated* for 1L NSCLC



*Patients starting 1L treatment within the last 1 month (Except Driver Mutation)

Source: Primary research results
(Nov 2020~Jul 2025: n=167~245)

The Clinical Trial Result of HCC 1L



CheckMate 9DW Study

	OPDIVO + YERVOY	Control Group (molecular-targeted drug)
OS	23.7 months	20.6 months
PFS	9.1 months	9.2 months
ORR	36%	13%
DOR	30.4 months	12.9 months
Three-years overall survival rates (follow-up data)	38%	24%
Steroid	29%*	-
Treatment-related death	3.6%	0.9%

* Percentage of high-dose steroid use

Lancet. 2025 May 24;405(10492):1851-1864.